Trial Profile
A 12-week, Double-blind, International, Multicenter, Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Oct 2020
Price :
$35
*
At a glance
- Drugs Beraprost (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Lung Rx
- 17 Jun 2014 New trial record